The contribution of CpG dinucleotides in the vector genome in activating the innate immune mechanisms upon cellular entry is first mentioned on page 14 of the briefing. Section 2.4.2 goes into more detail on TLR9-dependent immune induction and recommends “codon modification to remove CpGs” as a strategy to circumvent CpG-mediated immune activation (page 16).
This exclusive invite only event was a Symposium featuring panel conversations on the state of the U.S. Health Care System, the cost of prescription medication, and the ways to improve the patient experience hosted by Senator Susan Collins, Senator Jeanne Shaheen, Avik Roy, Matthew Fiedler, and Davis Liu.
This exclusive invite-only event was a series of discussions about challenges and opportunities for small businesses in today’s economic climate.
We have been awarded the Most Advanced Gene Therapy Vector Technology Company 2023.
Learn more about NxGEN’s technology to reduce the body’s immune reaction toward your AAV vectors, leading to safe, effective, and durable therapeutic gene expression in the Cell and Gene Therapy Supplement of Genetic Engineering & Biotechnology News (GEN) Magazine below.
Dr. Faust is a pioneer in this research and was the first to CpG-deplete AAV vectors to circumvent TLR9 activation, a technology that has become an industry standard.
Read about both of NxGEN’s gene therapy platforms:
1) NxGEN’s CpG-depletion technology of the AAV vector to achieve safe, effective, and durable
therapeutic gene expression.
2) NxGEN’s cardiac gene therapy to modulate the immune system to prevent chronic rejection without
the requirement for life-long anti-rejection medication, which can also be used for inflammatory
Click here to read the Article in GEN Magazine.